Table 1.
Baseline demographics and patient characteristics of the study cohort.
Fig 1.
Nelson-Aalen plot depicting the cumulative incidence of hepatocellular carcinoma (HCC) over time in the overall cohort of patients with chronic hepatitis B (CHB).
Fig 2.
Nelson-Aalen plots showing cumulative HCC incidence stratified by individual risk factors in the entire cohort, including the number of cardiometabolic risk factors (CMRFs), hypertension (HT), diabetes mellitus (DM), obesity, dyslipidemia (with and without statin use), hepatic steatosis, metabolic dysfunction-associated steatotic liver disease (MASLD), and cirrhosis.
Table 2.
Cumulative Incidence of HCC, Stratified by Cohort and aMAP Score Risk Group.
Fig 3.
Nelson-Aalen plots illustrating cumulative HCC incidence stratified by aMAP risk score categories (low, intermediate, high), with subgroup analyses based on MASLD status, presence of CMRFs, and obesity.
aMAP, Age-Male-ALBI-Platelet score; MASLD, metabolic ysfunction-associated steatotic liver disease; CMR, cardiometabolic risk.
Table 3.
Cox Regression Analysis for Factors Associated with HCC Development.
Fig 4.
Forest plot summarizing multivariable Cox regression analysis identifying factors independently associated with HCC development.
HCC, hepatocellular carcinoma; aHR, adjusted hazard ratio; ALP, alkaline phosphatase; ALT, alanine aminotransferase; DLP, dyslipidemia; HT, hypertension; DM, diabetes mellitus; CHB, chronic hepatitis B.